SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until end of 2023.